[1] |
LUO Yi, JIANG Zhiwei.
Statistical consideration in the design of COVID-19 clinical trials in emergency
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 121-125.
|
[2] |
WANG Ao, CAI Jingjing, BAI Jianling, LIU Yue, YU Xuanxuan, CHEN Feng, ZHAO Yang, YU Hao.
Sample size estimation for average bioequivalence for highly variable drugs using two replicated crossover designs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 164-170.
|
[3] |
BAI Jianling, CHEN Mengkai, YU Hao, ZHAO Yang, CAI Jingjing, HUANG Lihong, JIANG Zhiwei, CHEN Feng.
Two methods for assessing consistency probability in multiregional clinical trials: a comparison study
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(9): 1017-1021.
|
[4] |
CHEN Lin, LIU Yu-xiu, MIAO Hua-zhang.
Statistical performance comparison of different design methods of targeted clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 399-403.
|
[5] |
GUO Yang, JIANG Zhi-wei, XIA Jie-lai, WANG Yu-kun.
Statistical considerations of group sequential design in oncology clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(2): 175-180.
|
[6] |
WEN Shi-mei, CHEN Yun-fei, LIU Hua.
SAS programming for sample size and power calculation of measurement data in non-inferior trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(1): 51-54.
|
[7] |
CHENG Qi, LIU Yu-xiu, CHEN Lin, LIU Li-xia.
Exact method of sample size calculation and statistical inference in single-arm clinical trials with objective performance criteria
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 517-522.
|
[8] |
LI Chan-juan, JIANG Zhi-wei, WANG Rui, XIA Jie-lai.
Sample size estimation in randomized controlled drug clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1132-1136.
|
[9] |
LIU Yu-xiu, XU Xiao-li, ZHENG Jun.
Sample size estimation and hypothesis testing of assessing equivalence/noninferiority for paired binary data
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(3): 299-302.
|
[10] |
LU Jing-jing, CHEN Feng, CUI Yong-chun, WANG Shou-cang, ZHANG Ai-min, LI Ren-peng, XU Jin-ke.
Estimation of sample size in individual bioequivalence
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(2): 204-207.
|
[11] |
HE Ying-chun, ZHENG Qing-shan.
Clinical trial design of compound lisinopril in treatment essential hypertension in Chinese patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(12): 1427-1429.
|
[12] |
LU Jing-Jing, YU Hao1, CHEN Feng1.
Comparison of testing approaches to establishing equivalence on proportions
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(3): 354-357.
|
[13] |
ZHANG Gao-Kui, YAO Chen, XIA Jie-Lai.
Simulation method on power and sample size calculation in related rate non-inferior trial
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(2): 234-237.
|
[14] |
ZHENG Qing-Shan, SUN Rui-Yuan, CHEN Zhi-Yang.
Lowest sample size and its safety in clinical trials in China
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 354-355.
|